American Journal of Cardiology
Volume 104, Issue 10 , Pages 1317-1323, 15 November 2009

Prognostic Impact of Types of Atrial Fibrillation in Acute Coronary Syndromes

  • Dennis H. Lau, MBBS

      Affiliations

    • Cardiovascular Research Centre, Department of Cardiology, Royal Adelaide Hospital and Disciplines of Medicine and Physiology, University of Adelaide, Adelaide, South Australia, Australia
  • ,
  • Luan T. Huynh, MBBS

      Affiliations

    • Department of Cardiology, Flinders Medical Centre and Department of Medicine, Flinders University, Adelaide, South Australia, Australia
  • ,
  • Derek P. Chew, MBBS, MPH

      Affiliations

    • Department of Cardiology, Flinders Medical Centre and Department of Medicine, Flinders University, Adelaide, South Australia, Australia
  • ,
  • Carolyn M. Astley, BN

      Affiliations

    • Department of Cardiology, Flinders Medical Centre and Department of Medicine, Flinders University, Adelaide, South Australia, Australia
  • ,
  • Ashish Soman, MBBS

      Affiliations

    • Sanofi-Aventis, Macquerie Park, New South Wales, Australia
  • ,
  • Prashanthan Sanders, MBBS, PhD

      Affiliations

    • Cardiovascular Research Centre, Department of Cardiology, Royal Adelaide Hospital and Disciplines of Medicine and Physiology, University of Adelaide, Adelaide, South Australia, Australia
    • Corresponding Author InformationCorresponding author: Tel: (+61) 8-8222-2723; fax: (+61) 8-8222-2722

Received 19 March 2009; received in revised form 19 June 2009; accepted 19 June 2009. published online 28 September 2009.

Atrial fibrillation (AF) has been established as an independent predictor of long-term mortality after acute myocardial infarction. However, this is less well defined across the whole spectrum of acute coronary syndromes (ACSs). The Acute Coronary Syndrome Prospective Audit is a prospective multicenter registry with 12-month outcome data for 3,393 patients (755 with ST-segment elevation myocardial infarction, 1942 with high-risk non–ST-segment elevation ACS [NSTE-ACS], and 696 with intermediate-risk NSTE-ACS). A total of 149 patients (4.4%) had new-onset AF and 387 (11.4%) had previous AF. New-onset AF was more, and previous AF was less frequent in those with ST-segment elevation myocardial infarction than in those with high-risk NSTE-ACS or intermediate-risk NSTE-ACS (p <0.001). Compared to patients without arrhythmia, patients with new-onset AF and previous AF were significantly older and had more high-risk features at presentation (p <0.004). Patients with new-onset AF more often had left main coronary artery disease, resulting in a greater rate of surgical revascularization (p <0.001). Only new-onset AF resulted in adverse in-hospital outcomes (p <0.001). Only patients with previous AF had greater long-term mortality (hazard ratio 1.42, p <0.05). New-onset AF was only associated with a worse long-term composite outcome (hazard ratio 1.66, p = 0.004). However, the odds ratio for the composite outcome was greatest for patients with new-onset AF with intermediate-risk NSTE-ACS (odds ratio 3.9, p = 0.02) than for those with high-risk NSTE-ACS (odds ratio 2.0, p = 0.01) or ST-segment elevation myocardial infarction (odds ratio 1.4, p = 0.4). In conclusion, new-onset AF was associated with worse short-term outcomes and previous AF was associated with greater mortality even at long-term follow-up. The prognostic burden of new-onset AF differed with the type of ACS presentation.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This data collection for the ACACIA cohort was sponsored by Sanofi-Aventis, Australia Pty, Ltd., Macquerie Park, New South Wales, Australia. Dr. Lau was supported by a medical postgraduate scholarship from the National Health and Medical Research Council of Australia, Canberra, Australian Capital Territory, Australia; the Bakken Electrophysiology Scholarship from the University of Adelaide, Adelaide, South Australia, Australia; and a biomedical research scholarship from Kidney Health Australia, Melbourne, Victoria, Australia. Drs. Chew and Sanders were supported by the National Heart Foundation of Australia, Adelaide, South Australia, Australia.

PII: S0002-9149(09)01317-4

doi:10.1016/j.amjcard.2009.06.055

American Journal of Cardiology
Volume 104, Issue 10 , Pages 1317-1323, 15 November 2009